Cart
sales@molnova.com
SYR127063
CAS No. 871026-18-5
SYR127063( BDBM92454 )
Catalog No. M24884 CAS No. 871026-18-5
SYR127063 (BDBM92454) is a potent and selective HER2 inhibitor, binds to HER2 in a reactive conformation.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 272 | In Stock |
|
| 10MG | 408 | In Stock |
|
| 25MG | 672 | In Stock |
|
| 50MG | 945 | In Stock |
|
| 100MG | Get Quote | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameSYR127063
-
NoteResearch use only, not for human use.
-
Brief DescriptionSYR127063 (BDBM92454) is a potent and selective HER2 inhibitor, binds to HER2 in a reactive conformation.
-
DescriptionSYR127063 (BDBM92454) is a potent and selective HER2 inhibitor, binds to HER2 in a reactive conformation.
-
In Vitro——
-
In Vivo——
-
SynonymsBDBM92454
-
PathwayAngiogenesis
-
TargetHER/HSP
-
RecptorHER2/HER4/EGFR
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number871026-18-5
-
Formula Weight492.88
-
Molecular FormulaC23H20ClF3N4O3
-
Purity>98% (HPLC)
-
SolubilityDMSO:Soluble; Water: Insoluble
-
SMILESOCCOCCn(cc1)c2c1ncnc2Nc(cc1)cc(Cl)c1Oc1cc(C(F)(F)F)ccc1
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Aertgeerts K, et al. Structural analysis of the mechanism of inhibition and allosteric activation of the kinase domain of HER2 protein. J Biol Chem. 2011 May 27;286(21):18756-65.
molnova catalog
related products
-
BMS 599626 2HCl
BMS-599626 (AC480) is a selective inhibitor of HER1 and HER2 (IC50s: 20 nM and 30 nM) ~8-fold less potent to HER4 >100-fold to Lck VEGFR2 c-Kit MET etc.
-
EGFR-IN-99
EGFR-IN-99 (JBJ-03-142-02) is an EGFR and HER2 Exon 20 insertion mutation inhibitor with antiproliferative activity for the study of non-small cell lung cancer (NSCLC).
-
Pertuzumab
Pertuzumab anti-HER2) a humanized monoclonal antibody and the first in the class of agents called the HER2 dimerization inhibitors impairs the ability of HER2 to bind to other members of the HER family.
